Deferoxamine, an iron chelator, promotes revascularization via endothelial cells activation

被引：0
|
作者：
Ikeda, Yasumasa [1 ]
Tajima, Soichiro [1 ]
Yoshida, Sumiko [2 ]
Yamano, Noriko [1 ]
Kihira, Yoshitaka [1 ]
Ishizawa, Keisuke [3 ]
Aihara, Ken-ichi [2 ]
Tomita, Shuhei [1 ]
Tsuchiya, Koichiro [3 ]
Tamaki, Toshiaki [1 ]
机构：
[1] Univ Tokushima, Grad Sch Med, Dept Pharmacol, Tokushima 7708503, Japan
[2] Univ Tokushima, Grad Sch Med, Dept Med & Bio Sci, Tokushima 7708503, Japan
[3] Univ Tokushima, Grad Sch, Dept Med Pharmacol, Tokushima 7708503, Japan
来源：
JOURNAL OF PHARMACOLOGICAL SCIENCES | 2011年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：106P / 106P
页数：1
相关论文
共 50 条
  • [31] Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing
    Duscher, Dominik
    Januszyk, Michael
    Maan, Zeshaan N.
    Whittam, Alexander J.
    Hu, Michael S.
    Walmsley, Graham G.
    Dong, Yixiao
    Khong, Sacha M.
    Longaker, Michael T.
    Gurtner, Geoffrey C.
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2017, 139 (03) : 695E - 706E
  • [32] Copper induces, and the copper chelator tetrathiomolybdate inhibits, activation of human aortic endothelial cells
    Wei, Hao
    Zhang, Weijian
    Frei, Balz
    FASEB JOURNAL, 2008, 22
  • [33] Diabetes-induced endothelial dysfunction is prevented by long-term treatment with the modified iron chelator, hydroxyethyl starch conjugated-deferoxamine
    Pieper, GM
    Siebeneich, W
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1997, 30 (06) : 734 - 738
  • [34] Mechanical Stretch on Endothelial Cells Promotes Monocyte Activation and Differentiation into Immunogenic Dendritic Cells via STAT3.
    Loperena, Roxana
    Itani, Hana A.
    Gomez, Jose A.
    Engel, Noah
    Kirabo, Annet
    Harrison, David G.
    HYPERTENSION, 2017, 70
  • [35] Treatment with the Iron Chelator, Deferoxamine Mesylate, Alters Serum Markers of Oxidative Stress in Stroke Patients
    Selim, Magdy
    TRANSLATIONAL STROKE RESEARCH, 2010, 1 (01) : 35 - 39
  • [36] Treatment with the Iron Chelator, Deferoxamine Mesylate, Alters Serum Markers of Oxidative Stress in Stroke Patients
    Magdy Selim
    Translational Stroke Research, 2010, 1 : 35 - 39
  • [37] Blood compatibility of degradable macromolecular iron chelator starch conjugated deferoxamine (S-DFO)
    Mustafa, I.
    Abouhatab, A.
    Anwardeen, N. Rizwana
    Elkhair, W. Mohammed
    Afreen, F.
    Scott, M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 53 - 53
  • [38] IRON CHELATOR DEFEROXAMINE DECREASES SERUM OSTEOCALCIN CONCENTRATION AND NEGATIVELY AFFECTS BONE IN OVARIECTOMIZED MOUSE
    Gao, C.
    Xu, Y.
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 : S810 - S811
  • [39] Iron chelation with deferoxamine improves endothelial function in patients with atherosclerosis
    Duffy, SJ
    Biegelsen, ES
    Jewett, TA
    Holbrook, M
    Keaney, JF
    Vita, JA
    CIRCULATION, 1999, 100 (18) : 756 - 756
  • [40] EFFECTS OF IRON CHELATOR DEFEROXAMINE ON NUCLEOLAR MORPHOLOGIC AND FUNCTIONAL CHANGE AND CELL GROWTH IN HUMAN BREAST CANCER MCF-7 CELLS
    Liew, YihFong
    Lin, Yu-Shan
    Chen, Wei-Chih
    Cheng, Ya-Yun
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (03) : E51 - E51
12345